Biocept to Present at the LD Micro Virtual Invitational XI Conference on June 9, 2021

Rhea-AI Summary

Biocept, Inc. (Nasdaq: BIOC) announced that Michael Nall, President and CEO, will present at the LD Micro Virtual Invitational XI Conference on June 9, 2021. The company aims to update investors on CNSide™, its new assay for diagnosing tumors that have metastasized to the central nervous system. With a full commercial launch underway, CNSide™ could benefit around 200,000 patients annually in the U.S. Registration for the presentation is available online, and a webcast will be accessible on the company’s website for 90 days after the event.

Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that Michael Nall, President and CEO, will present at the LD Micro Virtual Invitational XI Conference on June 9, 2021 at 3:00 p.m. Eastern time (12:00 p.m. Pacific time).

“We look forward to providing investors with an update on CNSide™, our novel assay that provides physicians with a significantly improved tool to diagnose and manage patients with tumors that have metastasized to the central nervous system,” said Mr. Nall. “CNSide’s full commercial launch is now underway with the potential to provide critical information for the approximately 200,000 patients in the U.S. each year who have progression of their cancer to the central nervous system.”

Investors and other interested parties can register before Biocept’s presentation here. Following the presentation, the webcast will be available on the Company’s website for 90 days.

About Biocept

Biocept, Inc. develops and commercializes molecular diagnostic assays that provide physicians with clinically actionable information for treating and monitoring patients diagnosed with a variety of cancers. In addition to its broad portfolio of blood-based liquid biopsy assays, Biocept has developed the CNSide™ cerebrospinal fluid (CSF) assay that detects cancer that has metastasized to the central nervous system. Biocept’s patented Target Selector™ technology captures and quantitatively analyzes CSF tumor cells for tumor-associated molecular markers, using technology first developed for use in blood. Biocept also is leveraging its molecular diagnostic capabilities to offer nationwide COVID-19 RT-PCR testing to support public health efforts during this unprecedented pandemic. For more information, visit www.biocept.com. Follow Biocept on Facebook, LinkedIn and Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210603005099/en/

FAQ

What is the date of Biocept's presentation at the LD Micro Virtual Invitational XI Conference?

Biocept's presentation is scheduled for June 9, 2021.

What will Biocept discuss in its presentation at the LD Micro Conference?

Biocept will provide updates on CNSide™, a novel assay for diagnosing central nervous system tumors.

How many patients in the U.S. might benefit from Biocept's CNSide™ assay?

Approximately 200,000 patients with cancer progression to the central nervous system each year could benefit.

Where can I register for Biocept's presentation?

Registration for the presentation can be completed on Biocept's dedicated conference page.

Is the webcast of Biocept's presentation available after the event?

Yes, the webcast will be available on the company's website for 90 days following the presentation.